Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;22(1):1-2.
doi: 10.1038/s41575-024-00984-3.

Disease prevention trials in IBD: feasibility to future outlook

Sailish Honap  1   2   3 , Nelly Agrinier  4   5 , Silvio Danese  6 , Laurent Peyrin-Biroulet  7
Affiliations

Disease prevention trials in IBD: feasibility to future outlook

Sailish Honap et al. Nat Rev Gastroenterol Hepatol. 2025 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: S.H. served as a speaker, a consultant, an advisory board member and/or has received grants from Pfizer, Janssen, AbbVie, Takeda, Lilly, Ferring, and Pharmacosmos. S.D. has served as a speaker, consultant and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma and Vifor. L.P.-B. reports consulting fees from Abbvie, Abivax, Adacyte, Alimentiv, Amgen, Applied Molecular Transport, Arena, Banook, Biogen, BMS, Celltrion, Connect Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, IAC Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Nordic Pharma, Novartis, Oncodesign Precision Medicine, ONO Pharma, OSE Immunotherapeuthics, Pandion Therapeuthics, Par’ Immune, Pfizer, Prometheus, Protagonist, Roche, Samsung, Sandoz, Sanofi, Satisfay, Takeda, Telavant, Theravance, Thermo Fischer, Tigenix, Tillots, Viatris, Vectivbio, Ventyx and Ysopia; reports grants from Celltrion, Fresenius Kabi, Medac, MSD and Takeda; reports lecture fees from Abbvie, Amgen, Arena, Biogen, Celltrion, Ferring, Galapagos, Genentech, Gilead, Janssen, Lilly, Medac, MSD, Nordic Pharma, Pfizer, Sandoz, Takeda, Tillots and Viatris; and reports travel support from Abbvie, Amgen, Celltrion, Connect Biopharm, Ferring, Galapagos, Genentech, Gilead, Gossamer Bio, Janssen, Lilly, Medac, Morphic, MSD, Pfizer, Sandoz, Takeda, Thermo Fischer and Tillots. N.A. declares no competing interests.

References

    1. Rudbaek, J. J. et al. Deciphering the different phases of preclinical inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 21, 86–100 (2024). - DOI - PubMed
    1. Craig, P. et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 337, a1655 (2008). - DOI - PubMed - PMC
    1. Ananthakrishnan, A. N. et al. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. Lancet Gastroenterol. Hepatol. 7, 666–678 (2022). - DOI - PubMed
    1. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05211518 (2024).
    1. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05566587 (2022).

LinkOut - more resources